Amgen breaks ground on biomanufacturing plant in Rhode Island
August 02, 2018 – Amgen has broken ground on a next-generation biomanufacturing plant at its West Greenwich campus in Rhode Island, US.
The new plant, the first of its kind in the US, will use Amgen’s latest biomanufacturing capabilities to manufacture products for the US and global markets.
Amgen chairman and CEO Robert Bradway said: “Biologics manufacturing is a complex science and has long been a competitive advantage for Amgen.
“We are working to extend that advantage even further with a next-generation biomanufacturing plant in Rhode Island that will produce medicines to serve patients around the world suffering from serious illnesses.”
Next-generation biomanufacturing plants use multiple technologies in a single facility, which reduces the construction time and operating cost by half compared to a traditional plant.
These plants also require a smaller manufacturing footprint and offer greater environmental benefits in terms of reduced consumption of water and energy and lower levels of carbon emissions.
Furthermore, the equipment is portable, smaller and some components are disposable, allowing Amgen to quickly respond to changing demands for its medicines.
Rhode Island Governor Gina Raimondo said: “We are thrilled that Amgen has selected Rhode Island as the location for this plant that will be the first-of-its-kind in the United States.
“This is more proof that Rhode Island is now successfully competing for economic development opportunities with global companies thanks to our highly skilled workforce, robust academic institutions and exceptional quality of life.”
Amgen plans to invest up to $200m in the 120,000ft² manufacturing plant in Rhode Island. The plant is expected to create 150 additional highly-skilled manufacturing positions.
The existing Amgen Rhode Island plant houses one of the world’s largest mammalian protein manufacturing facilities. It manufactures commercial and clinical bulk drug substance.
Amgen has invested more than $1.5bn in its Rhode Island campus to add more than 500,000ft² of manufacturing, utility, administrative and laboratory space.
Amgen Rhode Island operations vice president Tia Bush said: “Since its inception in 2002, Amgen Rhode Island has evolved to a multi-product manufacturing facility, which is a testament to our focus on innovation, technology and great staff.
“Constructing this next-generation plant in Rhode Island further enhances our manufacturing capabilities within Amgen’s global operations network to deliver on our mission to serve patients.”